PortfoliosLab logo
Mainz Biomed B.V. (MYNZ)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

NL0015000LC2

IPO Date

Nov 5, 2021

Highlights

Market Cap

$7.11M

EPS (TTM)

-$22.71

Total Revenue (TTM)

$520.77K

Gross Profit (TTM)

$319.04K

EBITDA (TTM)

-$9.47M

Year Range

$2.65 - $40.40

Target Price

$14.00

Short %

6.34%

Short Ratio

0.75

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Mainz Biomed B.V., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%20.00%40.00%NovemberDecember2025FebruaryMarchApril
-99.12%
17.62%
MYNZ (Mainz Biomed B.V.)
Benchmark (^GSPC)

Returns By Period

Mainz Biomed B.V. had a return of -18.29% year-to-date (YTD) and -89.70% in the last 12 months.


MYNZ

YTD

-18.29%

1M

-17.33%

6M

-65.93%

1Y

-89.70%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

-6.06%

1M

-3.27%

6M

-4.87%

1Y

9.44%

5Y*

14.30%

10Y*

10.11%

*Annualized

Monthly Returns

The table below presents the monthly returns of MYNZ, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202540.97%-14.12%-38.62%9.97%-18.29%
2024-16.38%-8.85%16.49%-14.57%-1.22%-53.87%16.36%-24.20%-29.60%-1.61%-10.20%-50.91%-90.69%
2023-7.04%7.42%-11.42%-36.78%38.29%-12.93%-10.67%-28.34%-4.58%-31.16%-43.28%1.75%-83.66%
202251.30%-9.35%2.67%-14.97%-6.99%-20.05%2.16%-7.09%-21.47%2.97%23.55%-19.06%-31.67%
2021-2.50%6.67%4.00%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of MYNZ is 12, meaning it’s performing worse than 88% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of MYNZ is 1212
Overall Rank
The Sharpe Ratio Rank of MYNZ is 1919
Sharpe Ratio Rank
The Sortino Ratio Rank of MYNZ is 99
Sortino Ratio Rank
The Omega Ratio Rank of MYNZ is 1414
Omega Ratio Rank
The Calmar Ratio Rank of MYNZ is 22
Calmar Ratio Rank
The Martin Ratio Rank of MYNZ is 1616
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Mainz Biomed B.V. (MYNZ) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The chart of Sharpe ratio for MYNZ, currently valued at -0.60, compared to the broader market-2.00-1.000.001.002.003.00
MYNZ: -0.60
^GSPC: 0.46
The chart of Sortino ratio for MYNZ, currently valued at -1.23, compared to the broader market-6.00-4.00-2.000.002.004.00
MYNZ: -1.23
^GSPC: 0.77
The chart of Omega ratio for MYNZ, currently valued at 0.87, compared to the broader market0.501.001.502.00
MYNZ: 0.87
^GSPC: 1.11
The chart of Calmar ratio for MYNZ, currently valued at -0.90, compared to the broader market0.001.002.003.004.005.00
MYNZ: -0.90
^GSPC: 0.47
The chart of Martin ratio for MYNZ, currently valued at -1.28, compared to the broader market-5.000.005.0010.0015.0020.00
MYNZ: -1.28
^GSPC: 1.94

The current Mainz Biomed B.V. Sharpe ratio is -0.60. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Mainz Biomed B.V. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00NovemberDecember2025FebruaryMarchApril
-0.60
0.46
MYNZ (Mainz Biomed B.V.)
Benchmark (^GSPC)

Dividends

Dividend History


Mainz Biomed B.V. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2025FebruaryMarchApril
-99.68%
-10.07%
MYNZ (Mainz Biomed B.V.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Mainz Biomed B.V.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Mainz Biomed B.V. was 99.74%, occurring on Apr 1, 2025. The portfolio has not yet recovered.

The current Mainz Biomed B.V. drawdown is 99.68%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.74%Jan 24, 2022800Apr 1, 2025
-31.2%Nov 9, 202119Dec 6, 202121Jan 5, 202240
-11.02%Jan 19, 20222Jan 20, 20221Jan 21, 20223
-10.12%Jan 6, 20223Jan 10, 20222Jan 12, 20225

Volatility

Volatility Chart

The current Mainz Biomed B.V. volatility is 33.14%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%60.00%70.00%NovemberDecember2025FebruaryMarchApril
33.14%
14.23%
MYNZ (Mainz Biomed B.V.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Mainz Biomed B.V. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items